Selank is characterized as anxiolytic without sedation — it's studied for modulation of GABAergic signaling and enkephalin metabolism, alongside effects on cytokine balance tied to its tuftsin lineage (tuftsin itself is an immune-signaling fragment cleaved from a larger antibody protein). This distinguishes its claimed mechanism from Semax, its research cousin, which centers on BDNF-driven neurotrophic and dopaminergic effects rather than anxiety modulation.

‍

• Russia: late-stage/registered use for generalized anxiety disorder
• US: no legal retail pathway for human use; sold as a "research chemical" or sourced through compounding channels of uncertain current standing
• Anecdotal/off-label use for anxiety and stress modulation outside clinical settings

• Same Russian research lineage as Semax, but a structurally distinct peptide (tuftsin-derived vs. ACTH-derived) with a different target mechanism
• Regulatory status in the US 503A compounding framework is unsettled as of mid-2026 — sources differ on whether it currently sits in an authorized category, with some reporting it left the restricted list in 2024 and others noting it remains outside the approved bulk-substances list pending further review
• Not scheduled on the FDA's announced July 2026 Pharmacy Compounding Advisory Committee docket, unlike Semax